In August 2022, the European Medicines Agency granted Marketing Authorization to lenacapavir (Sunlenca), the first-in-class bi-annually dosed HIV capsid inhibitor indicated for multidrug-resistant HIV-1 infection.
This Premium deep dive into Sunlenca includes:
- the industry context
- the clinical data
- the target rationale
- the mechanism of action
- the drug’s origins
See our overview of all 36 of the novel small molecule and large molecule FDA approvals for 2022 here.
request a trial
You don’t have time to read everything, but you can’t afford to fall behind.
Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.
Get ahead now by requesting a trial.
